File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Whole genome and exome sequencing reveals the genetic landscape of burkitt lymphoma

TitleWhole genome and exome sequencing reveals the genetic landscape of burkitt lymphoma
Authors
Issue Date2011
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
The 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH 2011), San Diego, CA., 10-13 December 2011. In Blood, 2011, v. 118 n. 21, abstract 433 How to Cite?
AbstractBurkitt lymphoma (BL) is a relatively uncommon lymphoma, but is clinically important because it is curable when diagnosed properly. BL is also an important model disease for studying cancer. Chromosomal translocations of the MYC gene are a defining feature of BL. Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma in adults and demonstrates overlapping morphology, immunophenotype and clinical behavior with BL. The genetic causes and the role of specific mutations in BL are largely unknown. The decoding of the human genome and the advent of high-throughput sequencing have provided rich opportunities for the comprehensive identification of the genetic causes of cancer. We began by sequencing 2 complete lymphoma tumor genomes (and paired normal tissue) derived from DLBCL and BL respectively. The pattern of somatic base alterations in both DLBCL and BL genomes indicated a predominance of G A/C T and A G/T C transitions (P<10–6) suggesting that the majority of these mutations arise from endogenous processes rather than environmental exposures, as has been observed with lung cancer and tobacco. In order to comprehensively identify genes that are recurrently mutated in DLBCL and BL, we obtained a total of 95 cases of DLBCLs and 60 cases of BL. The DLBCL cases were divided into a discovery set (N=34) and a prevalence set (N=61). The Burkitt cases were also divided into discovery and prevalence sets (N=15, N=45 respectively). For each of the discovery set cases we also obtained paired normal tissue. We performed whole-exome sequencing for all of these using the Agilent solution-based system of exon capture, which uses RNA baits to target all protein coding genes (CCDS database), as well as 700 human miRNAs from miRBase (v13). In all, we generated over 6 GB of sequencing data using high throughput sequencing on the Illumina platform. We identified 525 candidate cancer genes that were recurrently somatically mutated in DLBCL and BL. We found that each tumor had an average of 20 gene alterations, which is fewer than most other solid tumors sequenced to date. Commonly implicated biological processes comprising these genes included signal transduction (e.g. PIK3CD, PDGFRA) and chromatin modification (e.g. MLL3, SETD2), affecting 17.2% and 14.8% of the total genetic events respectively. We found several genes related to cancer that were commonly mutated in both BL and DLBCL, including MYC, BTG1 and SETD2. Mutations in MYC were much more common in BL compared to DLBCL, suggesting that mutation of MYC might serve as an independent oncogenic mechanism in BL, in addition to chromosomal translocations. Many known cancer genes were found to be exclusively mutated in BL including SMARCA4, a gene known to regulate the expression of CD44 which is implicated in tumorigenesis. This study represents one of the first in-depth analyses of a BL genome and one of the largest applications of exome sequencing in cancer. Our data provide the most comprehensive genetic portrait of human BL to date, and provides a significant first step to identifying the genetic causes of the disease.
DescriptionOpen Access Journal
This journal issue is proceedings of ASH Conference 2011
Oral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Lymphomics - The Evolving Genetic Landscapes of Lymphoma
Persistent Identifierhttp://hdl.handle.net/10722/160324
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395

 

DC FieldValueLanguage
dc.contributor.authorLove, CLen_US
dc.contributor.authorJima, Den_US
dc.contributor.authorZhang, Jen_US
dc.contributor.authorGrubor, Ven_US
dc.contributor.authorMiles, RRen_US
dc.contributor.authorDunphy, CHen_US
dc.contributor.authorRichards, KLen_US
dc.contributor.authorChoi, WWLen_US
dc.contributor.authorAu, WYen_US
dc.contributor.authorSrivastava, Gen_US
dc.contributor.authorChadburn, Aen_US
dc.contributor.authorGordon, LIen_US
dc.contributor.authorEvens, AMen_US
dc.contributor.authorHsi, EDen_US
dc.contributor.authorCzader, Men_US
dc.contributor.authorRizzieri, DAen_US
dc.contributor.authorLagoo, ASen_US
dc.contributor.authorBernal-Mizrachi, Len_US
dc.contributor.authorMann, KPen_US
dc.contributor.authorSunay, Sen_US
dc.contributor.authorFlowers, CRen_US
dc.contributor.authorNaresh, Ken_US
dc.contributor.authorThompson, MAen_US
dc.contributor.authorGill, Jen_US
dc.contributor.authorDave, SSen_US
dc.date.accessioned2012-08-16T06:08:02Z-
dc.date.available2012-08-16T06:08:02Z-
dc.date.issued2011en_US
dc.identifier.citationThe 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH 2011), San Diego, CA., 10-13 December 2011. In Blood, 2011, v. 118 n. 21, abstract 433en_US
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/160324-
dc.descriptionOpen Access Journal-
dc.descriptionThis journal issue is proceedings of ASH Conference 2011-
dc.descriptionOral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Lymphomics - The Evolving Genetic Landscapes of Lymphoma-
dc.description.abstractBurkitt lymphoma (BL) is a relatively uncommon lymphoma, but is clinically important because it is curable when diagnosed properly. BL is also an important model disease for studying cancer. Chromosomal translocations of the MYC gene are a defining feature of BL. Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma in adults and demonstrates overlapping morphology, immunophenotype and clinical behavior with BL. The genetic causes and the role of specific mutations in BL are largely unknown. The decoding of the human genome and the advent of high-throughput sequencing have provided rich opportunities for the comprehensive identification of the genetic causes of cancer. We began by sequencing 2 complete lymphoma tumor genomes (and paired normal tissue) derived from DLBCL and BL respectively. The pattern of somatic base alterations in both DLBCL and BL genomes indicated a predominance of G A/C T and A G/T C transitions (P<10–6) suggesting that the majority of these mutations arise from endogenous processes rather than environmental exposures, as has been observed with lung cancer and tobacco. In order to comprehensively identify genes that are recurrently mutated in DLBCL and BL, we obtained a total of 95 cases of DLBCLs and 60 cases of BL. The DLBCL cases were divided into a discovery set (N=34) and a prevalence set (N=61). The Burkitt cases were also divided into discovery and prevalence sets (N=15, N=45 respectively). For each of the discovery set cases we also obtained paired normal tissue. We performed whole-exome sequencing for all of these using the Agilent solution-based system of exon capture, which uses RNA baits to target all protein coding genes (CCDS database), as well as 700 human miRNAs from miRBase (v13). In all, we generated over 6 GB of sequencing data using high throughput sequencing on the Illumina platform. We identified 525 candidate cancer genes that were recurrently somatically mutated in DLBCL and BL. We found that each tumor had an average of 20 gene alterations, which is fewer than most other solid tumors sequenced to date. Commonly implicated biological processes comprising these genes included signal transduction (e.g. PIK3CD, PDGFRA) and chromatin modification (e.g. MLL3, SETD2), affecting 17.2% and 14.8% of the total genetic events respectively. We found several genes related to cancer that were commonly mutated in both BL and DLBCL, including MYC, BTG1 and SETD2. Mutations in MYC were much more common in BL compared to DLBCL, suggesting that mutation of MYC might serve as an independent oncogenic mechanism in BL, in addition to chromosomal translocations. Many known cancer genes were found to be exclusively mutated in BL including SMARCA4, a gene known to regulate the expression of CD44 which is implicated in tumorigenesis. This study represents one of the first in-depth analyses of a BL genome and one of the largest applications of exome sequencing in cancer. Our data provide the most comprehensive genetic portrait of human BL to date, and provides a significant first step to identifying the genetic causes of the disease.-
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlooden_US
dc.titleWhole genome and exome sequencing reveals the genetic landscape of burkitt lymphomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailChoi, WWL: choiwl@hkucc.hku.hken_US
dc.identifier.emailAu, WY: auwing@hkucc.hku.hken_US
dc.identifier.emailSrivastava, G: gopesh@pathology.hku.hken_US
dc.identifier.authorityChoi, WWL=rp00247en_US
dc.identifier.authoritySrivastava, G=rp00365en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros203852en_US
dc.identifier.volume118-
dc.identifier.issue21-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 130326-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats